Dose dependent pharmacokinetics of midazolam

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacokinetics

Background:

• Midazolam is a commonly used sedative.
• Understanding its oral pharmacokinetics is crucial for safe and effective dosing.
• 1-hydroxymethylmidazolam is a primary active metabolite of midazolam.

Purpose of the Study:

• To investigate the pharmacokinetics of midazolam and its metabolite, 1-hydroxymethylmidazolam, after oral administration.
• To determine dose proportionality and identify potential non-linearities in midazolam's oral absorption and metabolism.

Main Methods:

• Oral administration of midazolam (7.5, 15, and 30 mg) to 12 healthy subjects.
• Measurement of midazolam and 1-hydroxymethylmidazolam plasma concentrations over time.
• Analysis of pharmacokinetic parameters including Cmax, AUC, and t1/2.

Main Results:

• Pharmacokinetics were dose-proportional between 7.5 mg and 15 mg oral midazolam.
• The 30 mg dose exhibited more-than-proportional increases in Cmax and AUC for both midazolam and 1-hydroxymethylmidazolam.
• A slight but significant increase in midazolam's elimination half-life (t1/2) was observed at the 30 mg dose.
• Potential saturation of midazolam first-pass metabolism was suggested at higher doses.

Conclusions:

• Oral midazolam pharmacokinetics are linear within the 7.5 mg to 15 mg dose range.
• Higher oral doses (30 mg) may lead to non-linear pharmacokinetics due to metabolic enzyme saturation.
• Observed non-linearities are unlikely to have clinical significance during therapeutic use.